|
Recent and Upcoming Public FDA Oncology Events
Applications for the 2024-2025 FDA-AACR Oncology Educational Fellowship are being accepted until August 1. This year-long program is aimed for hematology/oncology fellows, scientists, and early-career investigators, offering an in-depth exploration of the regulatory review process by blending didactic learning with practical cases discussing oncology drug approvals.
Check out Reflections and Roadmaps: Career Development Beyond the FDA-AACR Oncology Educational Fellowship in Clinical Cancer Research. This article highlights the experiences of four alumni, demonstrating the program's transformative impact on careers in government, academia, and industry. We hope you will consider applying!
The American Society of Clinical Oncology (ASCO) is now accepting applications for the October 24, 2024 Hybrid FDA-ASCO Fellows’ Day Workshop. Apply here by August 5! This one-day workshop is designed to support trainees interested in drug development by providing an introduction to the FDA, clinical trial design, oncology drug regulatory science and the drug/device approval process.
Dr. Jasmine Smith is a clinical reviewer in the Division of Oncology 3
What is your educational and professional background?
I am originally from Georgetown, SC, but I grew up as an Army brat, so I have lived throughout the East Coast and as far west as Arkansas. I attended undergrad at Spelman College in Atlanta, where I majored in Biology, and then returned to South Carolina for medical school at the University of South Carolina in Greenville. While I was in college, my little brother Lewis was diagnosed with osteosarcoma at age 14. He unfortunately passed away at age 20, when I was in medical school. His and our family’s experience pushed me towards pursuing pediatric oncology as my specialty. For a change of scenery, I journeyed West and completed a pediatrics residency at the University of Arizona in Tucson. I returned East for a pediatric hematology/oncology fellowship at St. Jude Children’s Research Hospital in Memphis, TN, which I completed this past June.
Why did you join FDA Oncology?
Throughout my medical training, there existed this constant internal struggle of maintaining emotional sanity while caring for families that reminded me so much of my own. And patients that reminded me so much of my brother. I appreciated the ability to deeply empathize and bond with my patients, but it was also becoming a form of emotional torture for myself. Though it was difficult to admit, I realized during my second year of fellowship that it was imperative for me to discover a different way to remain impactful within this field without risking my emotional and mental health. This opportunity to work for the FDA felt like the perfect way to remain connected with the field in a way that still provides plenty of opportunities for academic and career growth with a much broader impact on patients. I am looking forward to gaining more regulatory knowledge and finding my niche within the FDA oncology community. I hope to remain involved with all things involving pediatric oncology and sarcomas!
What do you like to do in your free time?
I am very much into the arts during my free time! I have always loved acting (and actually wanted to be an actress before the doctor thing happened). I enjoy performing in and watching plays, dancing, and attending music concerts/festivals. I also love travel, brunch, and more brunch!
|
Recent FDA Oncology Approvals
We've recently approved these oncology products—check the labeling for details on indications, dosages, side effects, trial design, efficacy results, and more!
July 22, 2024, Ribociclib in combination with fulvestrant to include all adults with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced or metastatic breast cancer as initial endocrine-based therapy or with disease progression following endocrine therapy.
Interested in learning more? Tune into our FDA Oncology Podcast. You can also take a look at this website How to Use Product Labeling and find full list of FDA oncology approvals online.
Recent FDA Oncology Publications
FDA approval summary: fam-trastuzumab deruxtecan-nxki for unresectable or metastatic non-small cell lung cancer with activating HER2 mutations. Oncologist.
Reflections and Roadmaps: Career Development Beyond the FDA-AACR Oncology Educational Fellowship. Clinical Cancer Research.
Moving Immunotherapy into the Treatment of Resectable Non–Small Cell Lung Cancer. American Society of Clinical Oncology Educational Book.
Project Socrates Educational Opportunities
FDA Oncology offers free educational programs for anyone interested in regulatory science and drug development. Check out the Project Socrates web page for more information.
Oncology Fellowship Program Directors: If you are interested in having FDA Oncology speak at your program, reach out to us at projectsocrates@fda.hhs.gov.
|
|
